On Wednesday, December 14, the first reading of the act on clinical trials of medicinal products for human use took place in the Sejm. The statements of the representatives of the parliamentary clubs at the Sejm rostrum showed that the deputies unanimously considered this project to be expected and necessary, both from the perspective of clinical trial participants and the clinical trials market.
Deputies emphasized the pro-patient nature of the solutions contained in the draft act, which ensure an even higher level of protection for patients, and also enable more efficient compensation of possible adverse effects. According to the deputies, the bill provides patients with a protective umbrella by introducing the Clinical Trials Compensation Fund.
Attentio...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
If you already have an account, please log in
